P776: A PHASE 2, OPEN-LABEL, ASCENDING DOSE STUDY OF KER-050 FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH VERY LOW, LOW, OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES

• S. Tan,
• A. Arbelaez,
• L. Chee,
• C. Y. Fong,
• D. Hiwase,
• G. Kannourakis,
• J. Kwan,
• J. Liang,
• A. Puliyayil,
• H. Rose,
• D. Ross,
• T.-C. Teh,
• D. Westerman,
• J. Wight,
• W. Feng,
• J. Lachey,
• A. McGinty,
• H. Natarajan,
• C. Rovaldi,
• S. Cooper

Affiliations

S. Tan

1 St Vincent’s Hospital, Melbourne

A. Arbelaez

2 Tweed Hospital, Tweed Heads

L. Chee

3 Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne

C. Y. Fong

4 Austin Health, Hiedleberg

D. Hiwase

5 Royal Adelaide Hospital, Adelaide

G. Kannourakis

6 Ballarat Oncology, Ballarat

J. Kwan

7 Westmead Hospital, Westmead, Australia

J. Liang

8 Middlemore Hospital, Auckland, New Zealand

A. Puliyayil

9 Albury Wodonga Health, Albury-Wodonga Regional Cancer Centre, Auckland

H. Rose

10 Barwon Health, Geelong

D. Ross

11 Flinders Medical Centre, Adelaide

T.-C. Teh

12 Box Hill Hospital, Eastern Health, Victoria

D. Westerman

13 1. Peter MacCallum Cancer Centre. 2. University of Melbourne, Melbourne

J. Wight

14 Townsville University Hospital, James Cook University, Douglas, Australia

W. Feng

15 Keros Therapeutics, Lexington, United States of America

J. Lachey

15 Keros Therapeutics, Lexington, United States of America

A. McGinty

15 Keros Therapeutics, Lexington, United States of America

H. Natarajan

15 Keros Therapeutics, Lexington, United States of America

C. Rovaldi

15 Keros Therapeutics, Lexington, United States of America

S. Cooper

15 Keros Therapeutics, Lexington, United States of America